"Breakthrough Flu Shot on the Horizon: FDA Advisory Panel to Review Moderna's Experimental mRNA Vaccine. In a significant development, the US Food and Drug Administration (FDA) is set to review Moderna's experimental mRNA flu shot, MFLUSIVA, in a move that could signal a return to a more stable and transparent approach to drug reviews following the controversy surrounding former agency head Marty Makary's departure. The FDA's Vaccine and Related Biological Products Advisory Committee will convene on June 18 to discuss and make recommendations on the safety and effectiveness of the vaccine, which uses a novel mRNA technology to combat the flu virus. If approved, MFLUSIVA could offer a more effective and potentially game-changing solution to the annual flu season, and investors and public health officials are eagerly awaiting the outcome of this critical review."
Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet June 18 to discuss and make recommendations on the safety and effectiveness of Moderna’s MFLUSIVA flu vaccine, according to a Federal Register notice published...
